Thirty years of HDAC inhibitors: 2020 hindsight

Ho, Terence C. S., Chan, Alex H. Y. and Ganesan, A. (2020) Thirty years of HDAC inhibitors: 2020 hindsight. Journal of Medicinal Chemistry, 63 (21). 12460–12484. ISSN 0022-2623

[img]
Preview
PDF (Accepted_Manuscript) - Accepted Version
Download (924kB) | Preview

Abstract

It is now thirty years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy, while many others are in clinical development for oncology as well as other therapeutic indications. This perspective reviews the biological and medicinal chemistry advances over the last three decades with an emphasis on the design of selective inhibitors that discriminate between the eleven human HDAC isoforms.

Item Type: Article
Uncontrolled Keywords: sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Science > School of Pharmacy
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 07 Jul 2020 23:58
Last Modified: 20 Oct 2021 03:03
URI: https://ueaeprints.uea.ac.uk/id/eprint/75951
DOI: 10.1021/acs.jmedchem.0c00830

Actions (login required)

View Item View Item